Mimir
Neues Mitglied
Hallo,
Pioglitazon ist ein Medikament, dass ursprünglich zur Behandlung von Insulinresistenz oder Diabetes entwickelt wurde. Studien zeigen jedoch, dass neben der Verbesserung des Blutzuckers und der Insulinresistenz das Medikament auch stark entzündungshemmende Eigenschaften hat.
Es gibt eine Studie in Bezug auf psoriasis athritis
"Results. After 12 weeks, six of 10 patients met the PsARC. The ACR20 response was achieved in five patients. The mean percentage reduction in PASI was 38%, with a clinically meaningful PASI 50 response in two of six patients. Median tender joint count (interquartile range) decreased from 12.0 (8.0–18.0) to 4.0 (2.0–10.0), and the median swollen joint count from 5.0 (4.0–8.0) to 2.0 (1.0–7.0) (P<0.05 for both). Median Health Assessment Questionnaire score changed from 1.0 (0.375–1.375) to 0.75 (0.375–1.0) (P<0.05). Three patients had to be withdrawn from the study due to inefficacy and side-effects. Major side-effects were oedema of the lower extremities and increase in weight.
Conclusions. Treatment with a PPARγ agonist appears to be a promising therapeutic principle in PsA, but the use of PPARγ ligands might be limited by side-effects such as increase in weight and fluid retention."
http://rheumatology.oxfordjournals.org/content/44/1/126.full
und Studien in Bezug auf rheumatische Erkrankungen generell:
"Objective:
To investigate the effect of pentoxifylline (PTX) and pioglitazone (Pg), each alone and in combination with methotrexate (MTX), on rheumatoid arthritis (RA) induced experimentally in male albino rats.
[...]
Results:
The anti-inflammatory properties of these drugs were confirmed by reduction of erythrocyte sedimentation rate, serum rheumatoid factor level, serum C-reactive protein level, serum tumor necrosis factor-a level, serum nitrite level, and blood superoxide dismutase level, whereas antioxidant activities were confirmed by an increase in the blood reduced glutathione level. Our study showed that Pg alone exerts portentous effects in the treatment of RA. However, it was more active in combination with MTX.
Conclusion:
Our study showed that Pg was the most potent drug in treating arthritic rats, followed by PTX, with lesser potency in treating arthritic rats. When comparing the two combinations, the combination of Pg with MTX was the most potent one. The second combination was the combination of PTX with MTX."
http://www.mmj.eg.net/article.asp?i...27;issue=4;spage=766;epage=774;aulast=Mohamed
Insbesondere für Leute mit einer Insulinresistenz oder Diabetes 2 könnte das ganze ja interessant sein.
Bei Leuten die mit Cortison behandelt werden ist ja eine Insulinresistenz nicht unwahrscheinlich...
Gruß
Pioglitazon ist ein Medikament, dass ursprünglich zur Behandlung von Insulinresistenz oder Diabetes entwickelt wurde. Studien zeigen jedoch, dass neben der Verbesserung des Blutzuckers und der Insulinresistenz das Medikament auch stark entzündungshemmende Eigenschaften hat.
Es gibt eine Studie in Bezug auf psoriasis athritis
"Results. After 12 weeks, six of 10 patients met the PsARC. The ACR20 response was achieved in five patients. The mean percentage reduction in PASI was 38%, with a clinically meaningful PASI 50 response in two of six patients. Median tender joint count (interquartile range) decreased from 12.0 (8.0–18.0) to 4.0 (2.0–10.0), and the median swollen joint count from 5.0 (4.0–8.0) to 2.0 (1.0–7.0) (P<0.05 for both). Median Health Assessment Questionnaire score changed from 1.0 (0.375–1.375) to 0.75 (0.375–1.0) (P<0.05). Three patients had to be withdrawn from the study due to inefficacy and side-effects. Major side-effects were oedema of the lower extremities and increase in weight.
Conclusions. Treatment with a PPARγ agonist appears to be a promising therapeutic principle in PsA, but the use of PPARγ ligands might be limited by side-effects such as increase in weight and fluid retention."
http://rheumatology.oxfordjournals.org/content/44/1/126.full
und Studien in Bezug auf rheumatische Erkrankungen generell:
"Objective:
To investigate the effect of pentoxifylline (PTX) and pioglitazone (Pg), each alone and in combination with methotrexate (MTX), on rheumatoid arthritis (RA) induced experimentally in male albino rats.
[...]
Results:
The anti-inflammatory properties of these drugs were confirmed by reduction of erythrocyte sedimentation rate, serum rheumatoid factor level, serum C-reactive protein level, serum tumor necrosis factor-a level, serum nitrite level, and blood superoxide dismutase level, whereas antioxidant activities were confirmed by an increase in the blood reduced glutathione level. Our study showed that Pg alone exerts portentous effects in the treatment of RA. However, it was more active in combination with MTX.
Conclusion:
Our study showed that Pg was the most potent drug in treating arthritic rats, followed by PTX, with lesser potency in treating arthritic rats. When comparing the two combinations, the combination of Pg with MTX was the most potent one. The second combination was the combination of PTX with MTX."
http://www.mmj.eg.net/article.asp?i...27;issue=4;spage=766;epage=774;aulast=Mohamed
Insbesondere für Leute mit einer Insulinresistenz oder Diabetes 2 könnte das ganze ja interessant sein.
Bei Leuten die mit Cortison behandelt werden ist ja eine Insulinresistenz nicht unwahrscheinlich...
Gruß
